Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder characterized by loss of motor neurons in motor cortex, brainstem, and spinal cord that results in muscle weakness and atrophy, spasticity, compromised speech, swallowing, and breathing. There is currently no effective treatment for ALS that can reverse the progression of the disease. The main possible treatments include drug therapy, stem cell transplantation, momentum transplantation, gene therapy, respiratory support, and nutritional management. The prognosis of ALS is poor, and the rate of disease progression varies greatly. Rapidly progressing patients may involve the respiratory system within a few months due to respiratory failure, requiring assisted ventilation or even death, and slower progressing ones can even survive for 10 years or longer. Since the vast majority of ALS is fatal, it is very important to assess the prognosis, which can help patients plan their lives better. Previous studies have confirmed that biological markers can be used as indicators for early diagnosis and prognosis of ALS. The purpose of this experiment is to explore the relationship between serum markers and amyotrophic lateral sclerosis function score and disease progression rate, which will play significant role in early diagnosis and effective treatment. Previous studies have confirmed that biological markers can be used as indicators for early diagnosis and prognosis of ALS. The purpose of this experiment is to explore the relationship between serum markers and amyotrophic lateral sclerosis function score and disease progression rate, which will play significant role in early diagnosis and effective treatment.